Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Benchmarks Nifty22,749.75-3.46FEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.32 % Invest NowFEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.45 % Invest NowEnter search…
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth. Despite declining operating margins, the firm anticipates improvements supported by product launches. Cipla remains focused on evaluating inorganic opportunities to enhance its specialty portfolio.
Listen to this article in summarized format
Loading...×ET Intelligence Group: Cipla's September-quarter earnings were impacted by a high base in the US business and weak sales of active pharmaceutical ingredients (API), leading to a softer year-on-year performance. However, the company's revenue and net profit grew sequentially, driven by growth in its India business, sustained momentum in branded prescription therapies, and improving traction in the US market led by respiratory products and a better product mix. With new respiratory launches and growing biosimilar pipeline, the company remains optimistic about growth momentum in the second half of FY27.India continues to remain the company's biggest growth engine, outperforming the overall domestic market. It delivered double-digit growth supported by respiratory, cardiac, anti-diabetes and dermatology therapies. With the rising share of chronic therapies and new product launches across segments, Cipla expects to sustain market share gains in the domestic business.
After a challenging year in the US market due to the normalization of revenue from certain products, Cipla bets on a recovery driven by respiratory launches. It received approval for generic Advair, its first dry-powder inhaler approved from its US manufacturing network. It expects contributions from additional respiratory and peptide products over the coming quarters. The company plans to strengthen its organic pipeline through 45-50 filings over the next three years. It expects to end FY27 with over $1 billion in revenue from the US market compared with $780 million in the previous year. It has entered into an exclusive agreement with Qilu Pharmaceutical to commercialize a biosimilar version of the cancer drug, Keytruda in the US and Canada, which should act as a long-term growth driver.
Read more: Vedanta Iron Q2 Results: Loss narrows to Rs 324 crore, revenue declines 2% YoY
While operating margin before depreciation and amortisation (Ebitda margin) declined 630 basis points year-on-year to 18.7%, it expanded 200 basis points sequentially amid tracion in the domestic business. It is expected to improve further in the second half of FY27, supported by respiratory product launches and a favourable product mix. It has retained the FY27 Ebitda margin guidance of 18.5%-20%.
Live Events
Backed by a net cash position of ₹9,823 crore, Cipla is actively evaluating inorganic opportunities, particularly in North America and Europe, with a focus on acquiring complex and differentiated products that can strengthen its specialty portfolio.
Read more: Jio’s big-bang listing may give it stock market’s No.2 crown after Reliance Industries
Cipla's stock has lost over 4% over the past three months, underperforming the 2.5% drop in the BSE Healthcare index. Despite weakness, the stock's trailing price-earnings (P/E) multiple at around 38 is above its five-year average multiple of 27. The stock is likely to remain range-bound until a clear sign of recovery in revenue and profits emerges.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onciplaCiplaRespiratory PipelineUS marketEbitda margingeneric Advair
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...moreless(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onciplaCiplaRespiratory PipelineUS marketEbitda margingeneric Advair
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...morelessPrime ExclusivesInvestment IdeasStock Report PlusePaperWealth EditionWill it be a regulatory nightmare if an exchange lists on its own platform?
KYC and KYB: Inside Damani’s Avenue Supermarts that refuses to charge more – Part 1 of 3
Will oil turn into a lingering problem? Is the world economy, India, or the market prepared?
KYB and KYC: Business behind the wealth creator called ‘Divi’s Lab’ – Part 2, concluding
KYB and KYC: Business behind the wealth creator called “Divi’s Lab” – Part 1
The global business of promising more
- 1
- 2
- 3
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET
Unlock Access to All Exclusives with ETPrime FREE TRIAL
15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers
Trial offer expiring in00 : 05 : 00
I'd rather pay ₹2599 nowUh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Prime Account Detected!
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.
Unlock ETPrime's Exclusive Stories Today!
Big Price Drop! Flat 40% Off
Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In nowOffer Exclusively For You
Save up to Rs. 700/-
ON ET PRIME MEMBERSHIP
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get Flat 40% Off
Then ₹ 1749 for 1 year
Avail OfferOffer Exclusively For You
ET Prime at ₹ 49 for 1 month
Then ₹ 1749 for 1 year
Avail OfferSpecial Offer
Get flat 40% off on ETPrime
Avail OfferAvail OfferClaim NowAlready a Member? Sign In nowNeed Assistance?
Connect with an ETPrime expert for personalized support and guidance
+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '' + h3 + '
' + h4 + '
- ' + listing + '
What’s Included with
ETPrime Membership
1Exclusive Insights That Matter
Uncover the truth with our investigative stories
Make strategic moves using the real-world case studies
Read industry-specific stories to identify emerging trends
Spot opportunities with in-depth insights that matter
Trump temper on H-1B visas is forcing Indians to do these things to stay put in US
What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.
Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?
The problem with lab grown diamonds
Why a falling rupee is a better option for the economy
A list of top 20 momentum stocks that have delivered massive returns in one year
2Invest Wisely With Smart Market Tools & Investment Ideas
Alpha Trade
Get daily trade ideas from SEBI-registered research analysts.
Investment Ideas
Grow your wealth with stock ideas & sectoral trends.
Stock Reports Plus
All-in-one stock research with Stock Score, peer comparison & key signals.
BigBull Portfolio
Get to know where the market bulls are investing to identify the right stocks.
Stock Analyzer
Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.
Market Mood
Analyze the market sentiments & identify the trend reversal for strategic decisions.
Stock Talk Live at 9 AM Daily
Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.
3Stay informed anytime, anywhere with ET ePaper
ePaper - Print View
Read the PDF version of ET newspaper. Download & access it offline anytime.
ePaper - Digital View
Read your daily newspaper in Digital View & get it delivered to your inbox everyday.
Wealth Edition
Manage your money efficiently with this weekly money management guide.
TOI ePaper
Read the PDF version of TOI newspaper. Download & access it offline anytime.
Deep Explainers
Explore the In-depth explanation of complex topics for everyday life decisions.
Health+ Stories
Get fitter with daily health insights committed to your well-being.
Personal Finance+ Stories
Manage your wealth better with in-depth insights & updates on finance.
5Enjoy Complimentary Subscriptions From Top Brands
Stream new documentaries from all across the world every day.
Stories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
